Previously embolized tumors can be more difficult to visualize and penetrate due to regions of necrosis and damaged vasculature.1
Tumor size can affect therapy efficacy
Lack of particle penetration may be the cause of poor response to embolization in patients with large (>5 cm) tumors.2
Multiple tumors can cause additional challenges
It can be difficult to deliver adequate treatment while minimizing injury to normal liver in patients with multiple tumors.3
Protecting the liver is critical
In patients with borderline liver function, the approach must achieve a two-fold goal of effective treatment while preserving adequate healthy liver tissue.4 Elevated liver biomarkers are associated with poor prognosis in HCC.5
Reduced vascularity limit pathways to penetration
It can be challenging to achieve adequate particle penetration into tumors with minimal or absent enhancement due to reduced vascularity.6
Why It Matters / How Patients Can Benefit
It’s about quality of life
In a comprehensive Real-World Evidence study, patients treated with SmartValve Technology experienced fewer in-patient visits and complications post-procedure.7,8
21% reduced
instance of fatigue (20.9% vs. 26.4%)7,8
61% reduced
incidence of gastric ulcers (1.8% vs. 4.7%)7,8
49% reduced
reports of jaundice (3.7% vs. 7.3%)7,8
Email this resource to yourself
We'll send you a download link of this resource to your inbox.
